Mukul Jain Sells Shares of SENS

Mukul Jain, the Chief Operating Officer of SENS, sold 16,194 shares of the company on June 15, 2026. The shares were sold at an average price of $7.18 each, bringing the total transaction value to approximately $116,272.92. This sale was not part of a pre-planned trading program.

Insider Buying and Selling at Senseonics Holdings, Inc.

On the same day, several other executives at SENS also sold shares. Kenneth Horton, the General Counsel, sold 9,545 shares. Brian Hansen, the Chief Commercial Officer, offloaded 5,420 shares. Francine Kaufman, the Chief Medical Officer, sold 4,010 shares. Frederick Sullivan, the Chief Financial Officer, sold 5,397 shares, while Timothy Goodnow, the President and CEO, sold 32,598 shares. All these transactions were executed at the same average price of $7.18 per share and were not under planned trading arrangements.

Other Institutional Activity in SENS

Looking at institutional activity, SESSA Capital IM, L.P. added 1,766,093 shares to its holdings, reaching a total of 1,766,093 shares valued at about $11.76 million. Vanguard Capital Management LLC also increased its position by 1,617,197 shares, ending with the same number of shares valued at roughly $10.77 million. BlackRock, Inc. reduced its holdings by 26,035 shares, leaving it with 568,729 shares worth approximately $3.79 million. Millennium Management LLC significantly increased its stake by 459,083 shares, now holding 560,371 shares valued at $3.73 million. Masters Capital Management LLC doubled its position by adding 250,002 shares, totaling 500,000 shares worth about $3.33 million.

Analysts Set New Price Targets

On May 12, 2026, HC Wainwright & Co. maintained its 'buy' rating for SENS, setting a price target of $14. Meanwhile, Stifel reiterated its 'hold' rating with a target of $8 on May 11, 2026. These ratings reflect the analysts' outlook on SENS's potential market performance.

About SENS

SENS is a company engaged in the development and commercialization of continuous glucose monitoring systems for diabetes management. The company focuses on providing innovative solutions to improve the quality of life for individuals with diabetes. SENS operates within the healthcare sector and is known for its commitment to advancing medical technology.

Bottom Line

Insider transactions, such as those by Mukul Jain and other SENS executives, often attract investor attention, although they do not necessarily indicate future stock performance. The recent activity among institutional investors shows varied strategies, with some increasing and others reducing their stakes. Analyst ratings provide additional insight, with recent price targets suggesting differing views on SENS's potential. As with all 13F filings and insider trades, these reports are backward-looking and may not reflect current positions.